Tumor antigen presentation changing the rules
Tumor antigen presentation changing the rules
复制标题
DOI：
10.1007/s002620050463
复制
发表时间：
1998-04-01
影响因子：
5.8
通讯作者：
Ostrand-Rosenberg, S
中科院分区：
文献类型：
--
作者：
Armstrong, TD;Pulaski, BA;Ostrand-Rosenberg, S
基于细胞的肿瘤疫苗的开发是基于肿瘤细胞可以被遗传修饰以直接将抗原呈递给T淋巴细胞的假设。与预期相反，交叉致敏是肿瘤特异性CD8（+）T细胞活化的主要途径，而抗原的直接呈递主导肿瘤特异性CD4（+）T细胞的活化。这些结果对免疫反应的产生提出了有趣的悖论，并对抗癌疫苗的开发具有明确的影响。
Cell-based tumor vaccines have been developed on the basis of the hypothesis that tumor cells can be genetically modified to present antigen to T lymphocytes directly. Contrary to expectations, cross-priming is the predominant pathway for activation of tumor-specific CD8(+) T cells, while direct presentation of antigen dominates activation of tumor-specific CD4(+) T cells. These results pose interesting paradoxes for the generation of immune responses, and have definite implications for the development of anti-cancer vaccines.